Get started
Author

Sandra Croockewit

Observed names: Croockewit, S., Croockewit, Sandra, S Croockewit, S. Croockewit, Sandra A. Croockewit, Sandra A. J. Croockewit, Sandra A.J. Croockewit, Sandra AJ Croockewit, Sandra J. Croockewit
Observed institutions: Radboud University Nijmegen, Radboud University Medical Center, University Medical Center Utrecht, de Duve Institute, Hovon, UCLouvain
ORCID: 0000-0003-3101-1194
Observed ORCID: 0000-0003-3101-1194
OpenAlex ID: A5087955804
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
2012 · Julien Haroche, Frédéric Charlotte, et al. · Blood · 691
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
2013 · Jurjen Tel, Erik H.J.G. Aarntzen, et al. · Cancer Research · 352
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
2003 · I Jolanda M de Vries, W Joost Lesterhuis, et al. · PubMed · 329
PDF
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
2009 · Henk M. Lokhorst, Bronno van der Holt, et al. · Blood · 275
PDF
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
2015 · Gerty Schreibelt, Kalijn F. Bol, et al. · Clinical Cancer Research · 241
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
2017 · H Goldschmidt, H M Lokhorst, et al. · Leukemia · 200
PDF
Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients
2011 · W. Joost Lesterhuis, I. Jolanda M. de Vries, et al. · Clinical Cancer Research · 192
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
2007 · H. M. Lokhorst, I. Schmidt-Wolf, et al. · Haematologica · 141
PDF
Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma
2009 · Susanne Lütje, Jacky W. J. de Rooy, et al. · Annals of Hematology · 129
PDF
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
2013 · C. Scheid, P. Sonneveld, et al. · Haematologica · 127
PDF
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
2010 · Pieter Sonneveld, Ingo Schmidt-Wolf, et al. · Blood · 88
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
2016 · Niels W.C.J. van de Donk, Henny G. Otten, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 82
PDF
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
2010 · W. Joost Lesterhuis, Gerty Schreibelt, et al. · Cancer Immunology Immunotherapy · 81
The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation
2011 · M Mohty, R F Duarte, et al. · Leukemia · 75
PDF
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
2015 · Kalijn F Bol, Carl G Figdor, et al. · OncoImmunology · 71
PDF
Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange
1999 · Margret B. Andresdottir, Nouaf Ajubi, et al. · Nephrology Dialysis Transplantation · 71
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
2016 · Kalijn F. Bol, Erik H. J. G. Aarntzen, et al. · Cancer Immunology Immunotherapy · 68
PDF
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
2024 · Kalijn F. Bol, Gerty Schreibelt, et al. · Nature Communications · 53
PDF
Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation
2004 · Jeroen K. J. Deegens, Margret B. Andresdottir, et al. · Transplant International · 53
Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation
2004 · Jeroen K. J. Deegens, Margret B. Andresdottir, et al. · Transplant International · 52
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma
2016 · Kalijn F. Bol, Thomas van den Bosch, et al. · Ophthalmology · 51
PDF
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)
2016 · Pieter Sonneveld, Meral Beksac, et al. · Blood · 35
Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
2019 · Monique C. Minnema, Kazem Nasserinejad, et al. · Haematologica · 34
PDF
Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods
2017 · Joannes F.M. Jacobs, Corrie M. de Kat Angelino, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 34
PDF
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
2018 · Niels WCJ van de Donk, Bronno van der Holt, et al. · The Lancet Haematology · 33
PDF
Works count: 91
Citation count: 3,857
H-index: 27
I10-index: 37
Year
Topic
Type